10-Q: Arcturus Therapeutics Reports Q1 2024 Results, Provides Update on Pipeline and Collaborations

Arcturus Therapeutics reported a net loss for Q1 2024, while highlighting progress in its mRNA vaccine and therapeutic programs, including key updates on its collaboration with CSL Seqirus.

Summary

• Arcturus Therapeutics reported a net loss of $26.8 million for the first quarter of 2024, compared to a net income of $50.8 million in the same period of 2023.
• The company's revenue decreased to $38 million from $80.3 million year-over-year, primarily due to a reduction in collaboration revenue from CSL Seqirus.
• Research and development expenses increased slightly to $53.6 million, driven by increased BARDA related expenses and early-stage program costs.
• The company's cash and cash equivalents, including restricted cash, totaled $345.3 million as of March 31, 2024.
• Arcturus continues to advance its mRNA vaccine and therapeutic pipeline, including its COVID-19 and influenza programs in collaboration with CSL Seqirus, and its proprietary programs for OTC deficiency and cystic fibrosis.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and collaborations, the significant decrease in revenue and net loss, along with identified internal control weaknesses, temper the overall sentiment. The company's future success is dependent on executing on milestones and securing additional funding.

Positives

• The company achieved a significant development milestone with CSL Seqirus, resulting in a $19.2 million payment.
• The ARCT-154 vaccine received approval in Japan and is under review in Europe, validating the company's mRNA technology.
• Positive results from the bivalent COVID-19 vaccine study in Japan support the platform's ability to adapt to new variants.
• The initiation of a Phase 3 study for the XBB1.5 COVID-19 vaccine candidate and a Phase 1 study for the LUNAR-qsFLU influenza vaccine demonstrate continued progress in the pipeline.
• The company's LUNAR-OTC and LUNAR-CF programs are advancing through clinical trials, with the latter receiving orphan drug designation in both the US and Europe.
• The company has a strong cash position of $345.3 million, providing financial stability for ongoing operations.

Negatives

• The company reported a net loss of $26.8 million for the quarter, a significant decrease from the net income of $50.8 million in the same period last year.
• Revenue decreased by 52.7% year-over-year, primarily due to lower collaboration revenue from CSL Seqirus.
• The company identified material weaknesses in internal control over financial reporting related to IT general controls and revenue recognition.
• The company experienced a $1.3 million lease impairment loss due to the abandonment of one of its facilities.
• The company is facing challenges with enrollment rates in Europe for the Phase 2 study of ARCT-810.

Risks

• The company's future success is dependent on the successful development and commercialization of its product candidates, which are subject to significant risks and uncertainties.
• The company may need to raise additional capital in the future, and there is no guarantee that it will be able to do so on acceptable terms.
• The company's collaboration agreements are subject to termination for convenience by its counterparties.
• The company's financial results are subject to fluctuations due to the timing of milestone payments and other revenue recognition.
• The company's internal control weaknesses could lead to material misstatements in its financial statements.
• The company is subject to risks associated with clinical trials, regulatory approvals, and competition from other companies in the biotechnology industry.

Future Outlook

Arcturus expects to continue to incur losses as it advances its pipeline and seeks regulatory approvals. The company anticipates that its current cash position will be sufficient to meet its anticipated cash requirements through at least the next twelve months. They will need to execute on milestones within the CSL Collaboration Agreement, raise additional debt or equity financing or enter into additional partnerships to fund development.

Management Comments

• Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued.
• Management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented.

Industry Context

This announcement comes at a time of increased focus on mRNA technology for vaccines and therapeutics. Arcturus is competing with other companies in the space, including Moderna and BioNTech, but is differentiated by its self-amplifying mRNA technology and LUNAR delivery platform. The collaboration with CSL Seqirus is a significant partnership that could accelerate the development and commercialization of Arcturus's products.

Comparison to Industry Standards

• Arcturus's Q1 2024 revenue of $38 million is significantly lower than the $80.3 million reported in Q1 2023, primarily due to a decrease in collaboration revenue from CSL Seqirus. This is a substantial decrease compared to other biotech companies that have established revenue streams from commercialized products.
• The company's net loss of $26.8 million in Q1 2024 contrasts with the net income of $50.8 million in Q1 2023. This shift is notable compared to other biotech companies that are either profitable or have a more consistent loss profile.
• Arcturus's research and development expenses of $53.6 million are in line with other clinical-stage biotech companies, but the increase of $1.8 million from Q1 2023 is relatively modest compared to companies that are rapidly expanding their clinical programs.
• The company's cash position of $345.3 million is strong compared to many other biotech companies, providing a runway for continued operations and development. However, the company's reliance on collaboration revenue and potential future capital raises is a risk factor.
• The approval of ARCT-154 in Japan is a significant achievement, making it the world's first approved self-amplifying RNA vaccine. This is a competitive advantage compared to other companies that are still in the clinical trial phase for their mRNA vaccines.
• The initiation of a Phase 3 study for the XBB1.5 COVID-19 vaccine candidate and a Phase 1 study for the LUNAR-qsFLU influenza vaccine are positive developments, but the company is still behind other companies that have already commercialized their COVID-19 vaccines and are further along in their influenza vaccine programs.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, as well as the identified internal control weaknesses.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Customers and partners may be impacted by any delays or changes in the company's development programs.
• Creditors may be concerned about the company's ability to repay its debts if it is unable to secure additional funding.

Next Steps

• Continue the Phase 2 trial of ARCT-810, the LUNAR-OTC candidate.
• Advance the LUNAR-CF program in clinical trials.
• Continue exploratory activities related to the platform.
• Continue to evaluate and advance manufacturing process and capabilities and technology transfers, and prepare for stockpiling and commercialization of COVID vaccines with CSL Seqirus.

Key Dates

Keywords

mRNA, vaccine, therapeutics, COVID-19, influenza, LUNAR, STARR, clinical trials, collaboration, CSL Seqirus, BARDA, OTC deficiency, cystic fibrosis